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Abstract 
 
Aims  Previous studies have suggested that plasma lipids are affected differently by the 
PPAR-γ agonists pioglitazone and rosiglitazone. The aim of this study was to perform a 
quantitative lipoprotein turnover study to determine the effects of PPAR-γ agonists on 
lipoprotein metabolism. 
Methods  24 subjects with type 2 diabetes treated with diet and/or metformin were 
randomised in a double blind study to receive 30mg pioglitazone, 8mg rosiglitazone or 
placebo once daily for 3 months. Before and after treatment absolute secretion rate (ASR) 
and fractional catabolic rate (FCR) of VLDL, IDL and LDL apolipoprotein B100 were 
measured with a 10 hour infusion of 1-13C leucine.  
Results  There was a significant decrease in HbA1c and non-esterified fatty acids with 
pioglitazone (p = 0.01; p = 0.02) and rosiglitazone (p = 0.04; p = 0.003) respectively, but 
no change in plasma triglyceride or HDL cholesterol. Following rosiglitazone there was a 
significant reduction in VLDL apo B ASR (p = 0.01) compared to baseline, a decrease in 
VLDL triglyceride/apoB (p = 0.01), an increase in LDL2 cholesterol (p = 0.02) and a 
decrease in LDL3 cholesterol (p = 0.02). There was a decrease in VLDL 
triglyceride/apoB (p = 0.04) in the pioglitazone group. There was no significant 
difference in change in VLDL ASR or FCR between the 3 groups. 
Conclusions  In patients with type 2 diabetes and normal lipids treatment with 
rosiglitazone or pioglitazone had no significant effect on lipoprotein metabolism 
compared to placebo. Treatment with rosiglitazone resulted in a decrease in small dense 
LDL. 
 
Keywords  intermediate density lipoprotein, low density lipoprotein, NEFA, PPAR-γ 
agonist, type 2 diabetes, very low density lipoprotein 
Abbreviations  α-ketoisocaproate: α-KIC Apolipopotein B100: apo B Absolute secretion 
rate: ASR Fractional catabolic rate: FCR Gas chromotography mass spectrometry: 
GCMS Gas chromatography combustion isotope ratio mass spectrometry: GC-C-IRMS 
High density lipoprotein: HDL, Homeostatic model assessment: HOMA Intermediate 
density lipoprotein: IDL Lipoprotein lipase: LPL Low density lipoprotein: LDL 
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MTBSTFA: N-methyl-N-(tertbutyldimethylsilyl)-trifluoroacetamide Non esterified fatty 
acid: NEFA Peroxisome proliferator activated receptor: PPAR Very low density 
lipoprotein: VLDL 
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Introduction 
The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists pioglitazone 
and rosiglitazone were introduced in Europe in 2000 and the USA in 1999 for the 
treatment of type 2 diabetes [1]. As well as reducing blood glucose and HbA1c there is 
also evidence that these PPAR-γ agonists affect plasma lipid levels [2]. Since 
dyslipidaemia in diabetes contributes to the increased risk of macrovascular disease the 
effect of these drugs on dyslipidaemia is important. Interest in this has increased recently 
since the publication of a meta-analysis suggesting increased cardiovascular risk with 
rosiglitazone. The authors postulated that the adverse effect of rosiglitazone on plasma 
lipids may be a possible mechanism behind this increased risk [3]. 
 
Large double-blinded, placebo controlled studies of rosiglitazone show that it increases 
total, high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol with 
no effect on triglyceride levels [4] [5] [6]. Similar studies with pioglitazone have found 
an increase in HDL cholesterol, a less consistent increase in LDL and total cholesterol 
and a reduction in triglyceride [7] [8] [9]. Systematic reviews [10] [11] have confirmed 
these differences. In the only head to head study 802 subjects with type 2 diabetes were 
randomised to pioglitazone 45mg or rosiglitazone 8mg for 24 weeks [12]. In the 
pioglitazone group there was a 12% reduction in triglyceride after 24 weeks treatment. In 
contrast in the rosiglitazone group there was an increase in triglyceride levels. HDL 
cholesterol and LDL cholesterol increased in both groups but the increase in HDL-
cholesterol was greater in the pioglitazone group and the increase in LDL-cholesterol was 
greater in the rosiglitazone group. There was no difference in the effect on HbA1c or 
cardiovascular parameters.  
 
The different effects of rosiglitazone and pioglitazone on lipid levels have yet to be 
explained. Lipoprotein turnover studies provide a methodology for investigating the 
mechanism behind changes in lipid concentrations. Several studies have investigated the 
effects of PPAR-γ agonists on lipoprotein turnover. The first, [13] randomised 24 
subjects with type 2 diabetes to 8 weeks treatment with placebo, 200mg troglitazone or 
600mg troglitazone. Very low density lipoprotein (VLDL) secretion was assessed using 
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1-13C leucine infusion. A reduction in VLDL apolipoprotein (apo) B ASR was found with 
600mg troglitazone which just failed to reach statistical significance. There was no other 
significant effect on lipoprotein turnover or lipid variables. In the second study [14] 8 
subjects received 30-45mg pioglitazone for 12-14 weeks. Following treatment there was 
a reduction in VLDL triglyceride and an increase in the FCR of VLDL triglyceride but no 
change in VLDL apo B ASR, VLDL triglyceride ASR or LDL ASR or FCR. In the third 
study there was no change in triglyceride apoB production and clearance rates in 17 men 
without diabetes following 6 weeks of rosiglitazone treatment [15]. The most recent 
study randomised 12 patients with type 2 diabetes to pioglitazone or rosiglitazone for 20 
weeks and found a reduction in hepatic de novo lipogenesis with pioglitazone but not 
rosiglitazone [16]. 
 
To determine the mechanism for the reported differences of pioglitazone and 
rosiglitazone on lipid levels, VLDL, intermediate density lipoprotein (IDL) and LDL apo 
B turnover were measured with stable isotopes in a placebo controlled double blind study 
in patients with type 2 diabetes.  
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Subjects and Methods 
 
24 subjects with type 2 diabetes for more than 6 months were recruited from the diabetes 
clinic of the Royal Surrey County Hospital in Guildford and 6 local primary care diabetes 
clinics. Subjects were on diet alone or metformin and no lipid lowering medication. 
Informed consent was obtained and the study was approved by the South West Surrey 
Ethics committee. Subjects were randomised into 3 groups, one group received 8mg 
rosiglitazone, one group received 30mg pioglitazone and the third group received placebo 
tablets. Subjects and investigators were blinded to treatment group.  
 
Before and after 3 months of treatment each subject had an identical metabolic study to 
measure lipoprotein turnover. After an overnight fast they were admitted to the clinical 
investigation unit and an intravenous cannula was inserted into each antecubital fossa. A 
bolus of 1-13C leucine (1mg/kg) (Cambridge Isotopes, Andover MA, USA) was 
administered followed by a constant infusion of 1-13C leucine (1mg/kg/hour) for 10 
hours. Subjects were allowed water only throughout the study. Blood samples were taken 
at baseline and at 30, 60, 90, 120, 150, 180, 240, 300, 360, 420, 480, 540 and 600 
minutes to measure VLDL, IDL and LDL apo B enrichment. At baseline and at 180, 360, 
540 and 600 minute samples were taken to measure the concentration of VLDL, IDL and 
LDL-cholesterol, triglyceride and apo B. Enrichment of α-ketoisocaproate (α-KIC) was 
measured at baseline, 180, 360, 530 and 600 minutes and was used to provide a measure 
of intracellular 13C leucine enrichment. In addition at baseline samples were taken for the 
measurement of LDL subfractions (LDL2 and LDL3), non esterified fatty acids 
(NEFAs), glucose, insulin and adiponectin. 
 
Samples for VLDL, IDL and LDL were separated by sequential density 
ultracentrifugation in a Beckman Coulter Optima LE80-K ultracentrifuge (High 
Wycombe, UK) with a type 50.4 Ti fixed angle rotor as previously described [17]. LDL2 
and LDL3 subfractions were separated from a baseline LDL fraction by adjusting the 
density to 1.044g/l then ultracentrifugation for 20h and removal of the top 1ml (LDL2). 
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The bottom fraction was then adjusted to density 1.063g/l followed by ultracentrifugation 
for 20h and removal of the top 1ml (LDL3). 
 
VLDL, IDL and LDL apo B was precipitated by isopropanol [18], and hydrolysed using 
hydrochloric acid. VLDL and IDL samples were derivatised with N-methyl-N-
(tertbutyldimethylsilyl)-trifluoroacetamide (MTBSTFA) VLDL and IDL apo B 
enrichment was measured using gas chromatography mass spectrometry (GCMS), 
(Agilent 5973 N MSD; Agilent Technologies, Bracknell, U.K.) in the electron impact 
mode with selected ion monitoring of [M-butyl]+ ions at mass to charge ratio (m/z) of 
302 and 303.  
 
Since the isotopic enrichment of LDL apo B is much lower than VLDL and IDL this was 
determined using a N-acetyl n-propyl ester derivative on a gas chromatography 
combustion isotope ratio mass spectrometer (GC-C-IRMS), specifically a Sira Series 2 
IRMS (VG Instruments, Hellingly, UK) coupled to an Orchid Gas Chromatograph 
Interface Module (Europa Scientific, Crewe, UK). Data were analysed using the 
manufacturer’s software (Orchid Post Processor, Version 2.3c. Europa Scientific). 
Isotope abundance was expressed relative to pulse peaks of reference CO2 gas. The 
enrichment of α-KIC, was measured as the quinoxalinol-tert-butyldimethylsilyl 
derivative. GCMS analysis used electron impact ionisation with selected ion monitoring 
of the ions at m/z 259 and 260.   
 
Apo B concentration was determined using an in-house sandwich enzyme-linked 
immunoassay method combining a polyclonal antibody against apo B (the Binding Site 
Ltd, Birmingham, UK) as capturing antibody and a monoclonal antibody raised 
specifically against apo B100 as second antibody (Ottawa Heart Institue, Ottawa, 
Canada). Triglyceride, cholesterol, VLDL, IDL, LDL apo B, triglyceride, cholesterol, 
HDL-cholesterol and NEFA concentrations were all determined using commercially 
available kits. Insulin was measured using an in-house double antibody 
radioimmunoassay (RIA). Glucose and HbA1c were measured on an ADVIA 1650 
Chemistry system (Bayer Healthcare, Leverusen, Germany). Plasma adiponectin was 
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measured by RIA using a commercially available kit from Linco Research Inc. (St. Louis, 
MO, USA). 
 
Data analysis 
Homeostatic model assessment insulin resistance index (HOMA2 IR) was calculated 
using the HOMA computer model (HOMA2, version 2.2) [19]. 
 
VLDL, IDL and LDL fractional secretion rate (FSR) was analysed using Simulation 
Analysis and Modelling (SAAM) II software, (SAAM, Seattle, WA, USA). This uses a 
multicompartmental model and incorporates a forcing function corresponding to 
precursor (α-KIC) enrichment and a delay function accounting for the amount of time 
required for synthesis and secretion of VLDL apo B. At steady state, shown by constant 
concentration of VLDL, IDL and LDL apo B, the proportion of apo B being removed 
from the circulation per unit time (fractional catabolic rate; FCR) is equal to the FSR. 
ASR (mg/kg/day) is the product of FSR and the apo B pool size divided by body weight 
(kg). Apo B pool size (mg) is the product of apo B concentration and plasma volume. 
Plasma volume was calculated using the method of Pearson [20]. 
 
Power calculation 
The primary endpoint was the change in VLDL secretion rate from baseline for each 
treatment versus the change from baseline for placebo. We estimated that a study with 8 
patients in each group would have a power of 80% to detect a difference of 45% in the 
production rate of VLDL at the 5% level of significance. For this calculation it was 
assumed that the standard deviation in production rate of VLDL apo B metabolism would 
be 30% (ref). Since an exercise programme which improves insulin sensitivity has been 
shown to reduce VLDL production rate by 49% [21] , a similar order of magnitude was 
expected for the glitazones. 
 
Statistical analysis 
Data is presented as mean ± SEM except for non-parametrically distributed variables 
(triglyceride, ASR and FCR) which is presented as median (interquartile range). 
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Comparison between variables at baseline was made using one way ANOVA or Kruskal-
Wallis for non-parametrically distributed variables. Post-hoc analysis was performed 
using the Bonferroni post-hoc test. Within each group, a comparison of variables before 
and after treatment was performed using Student’s t-test or Wilcoxon rank test for non-
parametrically distributed variables. Change in variables after treatment was compared 
across groups using ANOVA or Kruskal-Wallis as above. All statistical analysis was 
performed using SPSS. P values of less then 0.05 were regarded as significant. 
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Results 
Subjects’ baseline characteristics are summarised in table 1. Following 3 months of 
treatment there was a significant increase in weight in the pioglitazone group (p = 0.04). 
HbA1c decreased following treatment in the pioglitazone (-0.71% ± 0.20, p = 0.01) and 
rosiglitazone group (-0.48% ± 0.19, p = 0.04). There was a decrease in the IR component 
of HOMA2 in the rosiglitazone group (-0.34 ± 0.15, p = 0.06) but not in the pioglitazone 
group (-0.04, p = 0.83). 
 
Lipid concentrations 
Plasma lipid concentrations before and after treatment are summarised in table 2, 3 and 4. 
Prior to treatment plasma triglyceride, LDL cholesterol and HDL cholesterol were near 
normal. Only 6 subjects had a plasma triglyceride greater than 2.0mmol/l; 4 subjects had 
a LDL cholesterol greater than 3.0 mmol/l and 7 subjects had an HDL cholesterol below 
1mmol/l. 
 
There was a significant decrease in NEFAs with pioglitazone and rosiglitazone treatment 
(p= 0.02; p = 0.003 respectively) but no other change in lipid variables although there 
was a trend for an increase in HDL cholesterol in the rosiglitazone group (p = 0.07), table 
2. In the pioglitazone and the rosiglitazone groups there was a significant decrease in 
VLDL triglyceride/apo B, (p = 0.04, p = 0.01 respectively). There was no significant 
change in VLDL or IDL apo B, cholesterol, triglyceride or cholesterol/apo B in any of 
the groups. Following treatment there was a significant increase in LDL cholesterol in the 
placebo group and a significant increase in LDL cholesterol/apo B in the rosiglitazone 
group (p = 0.008), with a trend for a decrease in the pioglitazone group (p = 0.07) (table 
3). When LDL was subfractionated there was a significant increase in LDL 2 cholesterol 
and apo B (p = 0.02; p = 0.02) and a decrease in LDL 3 cholesterol and apo B (p = 0.02; 
p = 0.06) following rosiglitazone, table 4. 
 
Lipoprotein metabolism data 
The effects of treatment on lipoprotein metabolism are summarised in table 5. There was 
a significant decrease in VLDL apo B ASR in the rosiglitazone group following 
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treatment. There was no change in VLDL apo B ASR or FCR in the other 2 groups 
following treatment. There was no significant difference in the change in VLDL ASR or 
FCR between groups. There was no significant change in ASR or FCR of IDL and LDL 
apo B in any group following treatment.    
 
Adiponectin 
There was a significant increase in adiponectin in the pioglitazone and the rosiglitazone 
group following treatment (pioglitazone from 5.46µg/ml ± 1.07 to 10.34µg/ml ± 1.71, p = 
0.001, and rosiglitazone from 7.33µg/ml ± 1.16 to 15.93µg/ml ± 3.40, p = 0.002). 
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Table 1  
Baseline characteristics and changes following treatment 
 
 Placebo Pioglitazone Rosiglitazone 
Sex (M/F) 7/1 7/1 4/4 
Age (years) 60.75 ± 3.45 61.00 ± 3.93 66.50 ± 2.51 
Time since 
diagnosis 
(years) 
2.88 ± 0.40 4.00 ± 0.80 4.38 ± 1.03 
Number 
on 
metformin 
5 5 6 
 
 
Baseline 3 months Baseline 3 months Baseline 3 months 
Weight 
(kg) 
103.91 ± 
5.61 
104.38 ± 
5.76 
96.39 ± 3.62 
98.33 ± 
3.96a 
91.95 ± 6.52 92.63 ± 6.44 
BMI 
(kg/m2) 
31.96 ± 1.56 32.10 ± 1.64  30.81 ± 1.26 
31.45 ± 
1.45b 
29.99 ± 1.50 30.13 ± 1.45 
Fasting 
glucose 
(mmol/L) 
8.21 ± 0.36 8.55 ± 0.47 8.15 ± 0.30 8.15 ± 0.31 8.11 ± 0.75 6.83 ± 0.50 
HbA1c 
(%) 
 
6.60 ± 0.14 6.79 ± 0.24 7.53 ± 0.21c 6.81 ± 0.18d 6.94 ± 0.30 6.46± 0.19e 
HOMA2 
IR 
 
1.5 ± 0.30 1.84 ± 0.37 1.75 ± 0.30 1.71 ± 0.45 1.10 ± 0.18 0.76 ± 0.13f 
a p = 0.04 compared to baseline,  b p = 0.04 compared to baseline, c p = 0.03 compared to 
placebo, d p = 0.01 compared to baseline, e p = 0.04 compared to baseline, f p = 0.06 
compared to baseline 
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Table 2 
Lipid concentrations at baseline and after treatment 
 Placebo Pioglitazone Rosiglitazone 
Total cholesterol (mmol/L) 
Baseline 4.52 ± 0.19 5.14 ± 0.35 5.08 ± 0.29 
After treatment 4.77 ± 0.27 5.49 ± 0.41 5.32 ± 0.25 
LDL cholesterol (mmol/L) 
Baseline 2.06 ± 0.10 2.82 ± 0.33 2.42 ± 0.22 
After treatment 2.50 ± 0.19a 2.42 ± 0.27 2.58 ± 0.21 
Triglyceride (mmol/L) 
Baseline 2.15 (1.26, 2.44) 1.61 (1.42, 1.93) 1.38 (1.21, 1.68) 
After treatment 2.22 (1.76, 2.37) 2.12 (1.34, 2.55) 1.41 (1.17, 1.59)  
HDL cholesterol (mmol/L) 
Baseline  1.09 ± 0.06 1.23 ± 0.16 1.30 ± 0.08 
After treatment 1.15 ± 0.10 1.28 ± 0.17 1.45 ± 0.12b  
NEFA (mmol/L) 
Baseline  0.64 ± 0.06 0.66 ± 0.08 0.68 ± 0.09 
After treatment 0.72 ± 0.08 0.48 ± 0.04c 0.49 ± 0.10d 
a p = 0.03 compared to baseline, b p = 0.07 compared to baseline, c p = 0.02 compared to 
baseline, d p = 0.003 compared to baseline
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Table 3  
VLDL, IDL and LDL lipid concentrations before and after treatment  
 Placebo Pioglitazone Rosiglitazone 
VLDL apo B (mg/L) 
Baseline 46.26 ± 10.84 38.15 ± 5.84 31.88 ± 4.26 
After treatment 49.36 ± 10.86 44.20 ± 8.40 34.55 ± 5.67 
VLDL cholesterol (mmol/L) 
Baseline 0.47 ± 0.10 0.51 ± 0.12 0.28 ± 0.04 
After treatment 0.53 ± 0.10 0.54 ± 0.12 0.27 ± 0.04 
VLDL triglyceride (mmol/L) 
Baseline 1.44 (0.85, 1.87) 1.41 (0.92, 1.72) 0.85 (0.78, 0.98) 
After treatment 1.55 (1.17, 1.78) 1.17 (1.05, 1.58) 0.83 (0.69, 0.86) 
VLDL triglyceride/apo B 
Baseline  30.64 ± 6.19 31.04 ± 3.91 25.51 ± 2.70 
After treatment 34.56 ± 9.07 25.29 ± 3.71a 20.64 ± 2.47b 
IDL apo B (mg/L) 
Baseline 27.27 ± 4.04 35.05 ± 7.74 28.64 ± 4.45 
After treatment 24.63 ± 2.69 31.89 ± 7.24 35.04 ± 5.35 
IDL cholesterol (mmol/L) 
Baseline 0.089 ± 0.011 0.150 ± 0.034 0.096 ± 0.015 
After treatment 0.095 ± 0.011 0.145 ± 0.036 0.109 ± 0.014 
IDL triglyceride (mmol/L) 
Baseline 0.07 ± 0.009 0.10 ± 0.019 0.08 ± 0.011 
After treatment 0.08 ± 0.009 0.10 ± 0.025 0.08 ± 0.011 
IDL triglyceride/apo B 
Baseline  2.42 ± 0.33 2.71 ± 0.22 2.64 ± 0.24 
After treatment 2.86 ± 0.30 2.81 ± 0.16 2.68 ± 0.34 
LDL apo B (mg/L) 
Baseline 586.67 ± 28.01 715.42 ± 84.49 651.39 ± 73.73 
After treatment 618.61 ± 50.96 667.08 ± 54.78 640.00 ± 56.41 
LDL cholesterol/apoB 
Baseline 1.37±0.06             1.54±0.08 1.46±0.06 
After treatment 1.57±0.07 1.40±0.08c 1.56±0.05d 
LDL triglyceride (mmol/L) 
Baseline 0.33 ± 0.05 0.44 ± 0.07 0.37 ± 0.06 
After treatment 0.31 ± 0.07 0.38 ± 0.05 0.36 ± 0.06 
a
 p = 0.04 compared to baseline, b p = 0.01 compared to baseline, c p = 0.07 compared to baseline, d p = 
0.008 compared to baseline 
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Table 4  
LDL subfractions before and after treatment 
 Placebo Pioglitazone Rosiglitazone 
LDL2 cholesterol (mmol/L) 
Baseline 0.78 ± 0.08 1.08 ± 0.15 1.02 ± 0.14 
After treatment 0.80 ± 0.10 1.21 ± 0.07 1.39 ± 0.20a 
LDL3 cholesterol (mmol/L) 
Baseline 1.28 ± 0.16 1.25 ± 0.15 1.33 ± 0.12 
After treatment 1.41 ± 0.18 1.53 ± 0.23b 0.96 ± 0.14c 
LDL2 apo B (mmol/L) 
Baseline 0.21 ±0.02 0.26 ± 0.03 0.25 ± 0.03 
After treatment 0.21 ± 0.02 0.29 ± 0.03 0.34 ± 0.05d 
LDL3 apo B (mmol/L) 
Baseline 0.37 ± 0.05 0.37 ± 0.04 0.38 ± 0.05 
After treatment 0.41 ± 0.41 0.46 ± 0.07 0.30 ± 0.05e 
a
 p = 0.02 compared to baseline, b p = 0.05 compared to baseline, c p = 0.02 compared to 
baseline, p = 0.03 compared to placebo, p = 0.004 compared to pioglitazone, d p = 0.02 
compared to baseline, e p = 0.06 compared to baseline, p = 0.03 compared to pioglitazone 
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Table 5 
VLDL, IDL and LDL kinetic data 
 
Placebo Pioglitazone Rosiglitazone 
VLDL FCR (pools/day) 
Baseline 4.88 (3.91, 6.80) 4.15 (3.55, 5.83) 6.74 (5.80, 7.98) 
After treatment 4.18 (3.51, 5.50) 3.97 (3.63, 5.07) 5.75 (4.77, 6.53) 
VLDL ASR (mg/kg/day) 
Baseline 6.58 (5.06, 9.66) 5.68 (4.75, 6.54) 7.24 (6.28, 8.04) 
After treatment 6.24 (4.85, 8.60) 6.04 (5.03, 7.05) 5.83 (5.06, 6.84)a 
IDL FCR (pools/day) 
Baseline 4.80 (2.37, 5.90) 4.67 (2.76, 5.56) 7.63 (6.14, 8.12) 
After treatment 5.12 (3.60, 7.24) 4.13 (3.59, 5.66) 5.57 (5.02, 6.52) 
IDL ASR (mg/kg/day) 
Baseline 4.48 (2.55, 5.68) 3.60 (3.28, 6.23) 6.45 (5.51, 7.81) 
After treatment 3.76 (2.92, 5.72) 4.15 (3.24, 5.52) 6.22 (3.72, 8.74) 
LDL FCR (pools/day) 
Baseline 0.51 (0.43, 0.60) 0.41 (0.31, 0.54) 0.45 (0.40, 0.62) 
After treatment 0.53 (0.34, 0.60) 0.44 (0.29, 0.56) 0.48 (0.43, 0.72) 
LDL ASR (mg/kg/day) 
Baseline 10.33 (8.92, 10.71) 9.05 (7.41, 10.09) 10.77 (8.34, 13.22) 
After treatment 9.78 (9.00, 10.72) 9.60 (7.58, 11.04) 12.14 (8.81, 14.29) 
a
 p = 0.01 compared to baseline 
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Discussion 
This study compared the effect of placebo, pioglitazone and rosiglitazone on lipids and 
lipoprotein kinetics in patients with type 2 diabetes with near normal plasma lipid levels. 
There was a modest improvement in HbA1c and a decrease in NEFAs with pioglitazone 
and rosiglitazone. Although there was no significant change in plasma triglycerides there 
was a decrease in VLDL triglyceride/apo B suggesting a decrease in large VLDL 
particles (VLDL1) with both treatments. LDL cholesterol also did not change but there 
was an increase in large buoyant LDL cholesterol (LDL2) and a decrease in small dense 
LDL (LDL3) in the rosiglitazone group. There was no significant difference in 
lipoprotein metabolism after treatment between the 3 groups. The only significant finding 
was a reduction in VLDL apo B ASR in the rosiglitazone group, however there was no 
difference between treatment and placebo in this or any other measurement. 
 
The findings are surprising since previous studies have shown that the PPAR-γ agonists 
affect plasma lipids and that pioglitazone has a more favourable effect than rosiglitazone. 
A number of mechanisms may account for this. Subjects had well controlled plasma 
lipids and diabetes at baseline. The most marked changes in lipids seen in studies of the 
thiazolidinediones tend to be in subjects with dyslipidaemia at baseline. Indeed it has 
been suggested that the reason that pioglitazone is thought to have a more beneficial 
effect on lipids is that subjects in the original pioglitazone studies had more 
dyslipidaemia at baseline [11]. Mean LDL cholesterol at baseline was greater than 
3mmol/l in the 3 largest studies of rosiglitazone and pioglitazone [5] [6] [7] [8] [9] [22] 
and triglyceride was greater than 2.5mmol/L in 4 of these studies [5,7-9]. Since the 
publication of trials such as the Heart Protection Study [23] the lipid concentrations in the 
present study are more reflective of current targets and clinical practice.  
 
In previous studies of PPAR-γ agonists changes in lipid concentrations have been 
relatively small. The increase in HDL cholesterol with pioglitazone and rosiglitazone has 
been reported to be between 10 and 15%, the increase in LDL and total cholesterol with 
rosiglitazone is of a similar magnitude and the reduction in triglyceride with pioglitazone 
varies from 5 to 24% but is usually about 10%. In a head to head study [12] the change in 
triglyceride was -12% and +15%, the change in total cholesterol was +5.7% and +15.9% 
and the change in HDL cholesterol was +14.9% and +7.8% with pioglitazone and 
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rosiglitazone respectively.  In a recent study in younger men without diabetes (mean age 
48 years) with BMI ranging from 20.0 to 41.6 kg/m2 and triglyceride levels between 0.61 
and 4.0mmol/l rosiglitazone was shown to increase triglycerides by 32 % [15]. In contrast 
a number of studies have shown rosiglitazone to have no significant effect on plasma 
triglycerides as in the current study [4], [5]. 
 
Despite the lack of change in lipid levels in the current study there were changes in 
VLDL and LDL particle sizes. In both treatment groups there was a significant decrease 
in VLDL/apo B suggesting a decrease in large VLDL (VLDL1). A recent study has 
shown that the increase in VLDL triglyceride in diabetes is due to an increase in VLDL1 
production rate and that VLDL2 production rate is unaffected by diabetes [24]. This 
suggests that VLDL1 and VLDL2 are independently regulated. It has been suggested that 
the increased VLDL1 in type 2 diabetes results in an increase in small dense LDL and a 
reduction in HDL, increasing the risk of atherosclerosis [25]. However a decrease in 
small dense LDL (LDL3), an increase in large buoyant LDL (LDL2) and an increase in 
HDL cholesterol was found in the rosiglitazone treated group but not in the pioglitazone 
group. This effect of rosiglitazone to shift LDL phenotype from dense to large buoyant 
subfractions has been reported in animal [26] and human studies [27] and may explain 
the tendency of rosiglitazone to increase LDL cholesterol.  
 
Despite the similar changes in VLDL triglyceride/apo B with rosiglitazone and 
pioglitazone there was no change in VLDL apo B ASR compared to placebo although 
there was a significant reduction compared to baseline in the rosiglitazone group. There 
was a similar decrease in NEFAs in both groups. There is evidence that increased 
delivery of plasma NEFAs to the liver increases hepatic triglyceride  synthesis and the 
assembly of VLDL and that this is fundamental in the development of diabetic 
dyslipidaemia [28]. Since VLDL apo B ASR was not decreased compared to placebo in 
either treatment factors other than NEFA flux must be important in controlling VLDL 
apo B ASR.  
 
A study performed in a hamster model of insulin resistance [29] showed that 
rosiglitazone reduced VLDL apo B secretion rate with no effect on VLDL triglyceride 
clearance rate with an associated reduction in  expression of microsomal transfer protein. 
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Similarly troglitazone (600mg per day) has been shown to decrease VLDL apo B ASR 
with no effect on VLDL apo B FCR [13] whereas a recent study found no change in the 
ASR or FCR of triglyceride rich apoB in men without diabetes treated with rosiglitazone 
when compared to placebo [15].  
 
The lack of effect of pioglitazone on VLDL apo B kinetics is in keeping with previous 
studies. Treatment with 30-45mg of pioglitazone for 12-14 weeks in patients with type 2 
diabetes was shown to have no effect on VLDL apo B kinetics [14]. The patients in this 
study had a much greater triglyceride than the current study (triglyceride was > 
2.0mmol/l in 6 out of 8 patients) and pioglitazone reduced plasma triglyceride and VLDL 
triglyceride with no change in VLDL apo B suggesting a decrease in particle size as in 
the current study. There was an increased FCR of VLDL triglyceride, but there was no 
change in VLDL triglyceride ASR. Fibrates have also been shown to increase the FCR of 
VLDL [30], explained by hepatic activation of PPAR-α increasing expression of 
lipoprotein lipase and decreasing hepatic apo CIII synthesis. Pioglitazone may thus have 
PPAR-α like action. The lack of this effect in the current study may be due to the lower 
triglyceride concentrations. 
 
This study demonstrates that in people with diabetes and well controlled lipids that 
although the addition of rosiglitazone and pioglitazone had no effect of plasma 
triglycerides or LDL cholesterol there was a decrease in VLDL triglyceride/apo B ratio 
suggesting a shift from large VLDL1 to small VLDL2. In addition rosiglitazone increased 
large buoyant LDL and decreased small dense LDL, an effect not seen with pioglitazone. 
This may explain the reported effects of rosiglitazone to increase LDL cholesterol, an 
effect which has been postulated to be the cause of the increased cardiovascular risk seen 
with this drug.  
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